nodes	percent_of_prediction	percent_of_DWPC	metapath
Desvenlafaxine—Interstitial lung disease—Vandetanib—thyroid cancer	0.0281	0.0281	CcSEcCtD
Desvenlafaxine—Proteinuria—Vandetanib—thyroid cancer	0.0226	0.0226	CcSEcCtD
Desvenlafaxine—Protein urine present—Vandetanib—thyroid cancer	0.0223	0.0223	CcSEcCtD
Desvenlafaxine—Interstitial lung disease—Sorafenib—thyroid cancer	0.0189	0.0189	CcSEcCtD
Desvenlafaxine—Myocardial ischaemia—Sorafenib—thyroid cancer	0.0167	0.0167	CcSEcCtD
Desvenlafaxine—Proteinuria—Sorafenib—thyroid cancer	0.0153	0.0153	CcSEcCtD
Desvenlafaxine—Protein urine present—Sorafenib—thyroid cancer	0.015	0.015	CcSEcCtD
Desvenlafaxine—Bone disorder—Sorafenib—thyroid cancer	0.0148	0.0148	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Vandetanib—thyroid cancer	0.0145	0.0145	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Vandetanib—thyroid cancer	0.0144	0.0144	CcSEcCtD
Desvenlafaxine—Blood pressure increased—Sorafenib—thyroid cancer	0.0134	0.0134	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Vandetanib—thyroid cancer	0.0114	0.0114	CcSEcCtD
Desvenlafaxine—Weight decreased—Vandetanib—thyroid cancer	0.0113	0.0113	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Desvenlafaxine—Epistaxis—Vandetanib—thyroid cancer	0.0105	0.0105	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Vandetanib—thyroid cancer	0.00986	0.00986	CcSEcCtD
Desvenlafaxine—Urethral disorder—Vandetanib—thyroid cancer	0.00978	0.00978	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Sorafenib—thyroid cancer	0.00977	0.00977	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Vandetanib—thyroid cancer	0.00944	0.00944	CcSEcCtD
Desvenlafaxine—Eye disorder—Vandetanib—thyroid cancer	0.00933	0.00933	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Vandetanib—thyroid cancer	0.00926	0.00926	CcSEcCtD
Desvenlafaxine—Angiopathy—Vandetanib—thyroid cancer	0.00906	0.00906	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Vandetanib—thyroid cancer	0.009	0.009	CcSEcCtD
Desvenlafaxine—Alopecia—Vandetanib—thyroid cancer	0.00882	0.00882	CcSEcCtD
Desvenlafaxine—Breast disorder—Sorafenib—thyroid cancer	0.0088	0.0088	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00876	0.00876	CcSEcCtD
Desvenlafaxine—Mental disorder—Vandetanib—thyroid cancer	0.00874	0.00874	CcSEcCtD
Desvenlafaxine—Malnutrition—Vandetanib—thyroid cancer	0.00869	0.00869	CcSEcCtD
Desvenlafaxine—Dysgeusia—Vandetanib—thyroid cancer	0.00851	0.00851	CcSEcCtD
Desvenlafaxine—Vision blurred—Vandetanib—thyroid cancer	0.00819	0.00819	CcSEcCtD
Desvenlafaxine—Tremor—Vandetanib—thyroid cancer	0.00814	0.00814	CcSEcCtD
Desvenlafaxine—Erectile dysfunction—Sorafenib—thyroid cancer	0.00775	0.00775	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Vandetanib—thyroid cancer	0.00764	0.00764	CcSEcCtD
Desvenlafaxine—Weight decreased—Sorafenib—thyroid cancer	0.00761	0.00761	CcSEcCtD
Desvenlafaxine—Convulsion—Vandetanib—thyroid cancer	0.00753	0.00753	CcSEcCtD
Desvenlafaxine—Hypertension—Vandetanib—thyroid cancer	0.0075	0.0075	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00744	0.00744	CcSEcCtD
Desvenlafaxine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00739	0.00739	CcSEcCtD
Desvenlafaxine—Anxiety—Vandetanib—thyroid cancer	0.00737	0.00737	CcSEcCtD
Desvenlafaxine—Myocardial infarction—Sorafenib—thyroid cancer	0.00735	0.00735	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00735	0.00735	CcSEcCtD
Desvenlafaxine—Dry mouth—Vandetanib—thyroid cancer	0.00723	0.00723	CcSEcCtD
Desvenlafaxine—Epistaxis—Sorafenib—thyroid cancer	0.00707	0.00707	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Vandetanib—thyroid cancer	0.00695	0.00695	CcSEcCtD
Desvenlafaxine—Skin disorder—Vandetanib—thyroid cancer	0.00689	0.00689	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00665	0.00665	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00662	0.00662	CcSEcCtD
Desvenlafaxine—Urethral disorder—Sorafenib—thyroid cancer	0.0066	0.0066	CcSEcCtD
Desvenlafaxine—Insomnia—Vandetanib—thyroid cancer	0.00641	0.00641	CcSEcCtD
Desvenlafaxine—Paraesthesia—Vandetanib—thyroid cancer	0.00637	0.00637	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Sorafenib—thyroid cancer	0.00637	0.00637	CcSEcCtD
Desvenlafaxine—Tinnitus—Sorafenib—thyroid cancer	0.00628	0.00628	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Sorafenib—thyroid cancer	0.00625	0.00625	CcSEcCtD
Desvenlafaxine—Decreased appetite—Vandetanib—thyroid cancer	0.00616	0.00616	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00612	0.00612	CcSEcCtD
Desvenlafaxine—Fatigue—Vandetanib—thyroid cancer	0.00611	0.00611	CcSEcCtD
Desvenlafaxine—Angiopathy—Sorafenib—thyroid cancer	0.00611	0.00611	CcSEcCtD
Desvenlafaxine—Immune system disorder—Sorafenib—thyroid cancer	0.00608	0.00608	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00607	0.00607	CcSEcCtD
Desvenlafaxine—Constipation—Vandetanib—thyroid cancer	0.00606	0.00606	CcSEcCtD
Desvenlafaxine—Alopecia—Sorafenib—thyroid cancer	0.00595	0.00595	CcSEcCtD
Desvenlafaxine—Mental disorder—Sorafenib—thyroid cancer	0.0059	0.0059	CcSEcCtD
Desvenlafaxine—Malnutrition—Sorafenib—thyroid cancer	0.00586	0.00586	CcSEcCtD
Desvenlafaxine—Dysgeusia—Sorafenib—thyroid cancer	0.00574	0.00574	CcSEcCtD
Desvenlafaxine—Bone disorder—Epirubicin—thyroid cancer	0.00549	0.00549	CcSEcCtD
Desvenlafaxine—Angioedema—Sorafenib—thyroid cancer	0.00536	0.00536	CcSEcCtD
Desvenlafaxine—Syncope—Sorafenib—thyroid cancer	0.00526	0.00526	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Sorafenib—thyroid cancer	0.00515	0.00515	CcSEcCtD
Desvenlafaxine—Asthenia—Vandetanib—thyroid cancer	0.00509	0.00509	CcSEcCtD
Desvenlafaxine—Bone disorder—Doxorubicin—thyroid cancer	0.00508	0.00508	CcSEcCtD
Desvenlafaxine—Hypertension—Sorafenib—thyroid cancer	0.00506	0.00506	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00496	0.00496	CcSEcCtD
Desvenlafaxine—Abnormal dreams—Epirubicin—thyroid cancer	0.0049	0.0049	CcSEcCtD
Desvenlafaxine—Dry mouth—Sorafenib—thyroid cancer	0.00488	0.00488	CcSEcCtD
Desvenlafaxine—Diarrhoea—Vandetanib—thyroid cancer	0.00485	0.00485	CcSEcCtD
Desvenlafaxine—Shock—Sorafenib—thyroid cancer	0.00471	0.00471	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Sorafenib—thyroid cancer	0.00469	0.00469	CcSEcCtD
Desvenlafaxine—Dizziness—Vandetanib—thyroid cancer	0.00469	0.00469	CcSEcCtD
Desvenlafaxine—Skin disorder—Sorafenib—thyroid cancer	0.00465	0.00465	CcSEcCtD
Desvenlafaxine—Abnormal dreams—Doxorubicin—thyroid cancer	0.00453	0.00453	CcSEcCtD
Desvenlafaxine—Vomiting—Vandetanib—thyroid cancer	0.00451	0.00451	CcSEcCtD
Desvenlafaxine—Rash—Vandetanib—thyroid cancer	0.00447	0.00447	CcSEcCtD
Desvenlafaxine—Dermatitis—Vandetanib—thyroid cancer	0.00447	0.00447	CcSEcCtD
Desvenlafaxine—Headache—Vandetanib—thyroid cancer	0.00444	0.00444	CcSEcCtD
Desvenlafaxine—Nausea—Vandetanib—thyroid cancer	0.00421	0.00421	CcSEcCtD
Desvenlafaxine—Decreased appetite—Sorafenib—thyroid cancer	0.00416	0.00416	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00413	0.00413	CcSEcCtD
Desvenlafaxine—Fatigue—Sorafenib—thyroid cancer	0.00412	0.00412	CcSEcCtD
Desvenlafaxine—Constipation—Sorafenib—thyroid cancer	0.00409	0.00409	CcSEcCtD
Desvenlafaxine—Hot flush—Epirubicin—thyroid cancer	0.00385	0.00385	CcSEcCtD
Desvenlafaxine—Menopausal symptoms—Epirubicin—thyroid cancer	0.00381	0.00381	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Epirubicin—thyroid cancer	0.00361	0.00361	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.0036	0.0036	CcSEcCtD
Desvenlafaxine—Hot flush—Doxorubicin—thyroid cancer	0.00356	0.00356	CcSEcCtD
Desvenlafaxine—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Sorafenib—thyroid cancer	0.00352	0.00352	CcSEcCtD
Desvenlafaxine—Asthenia—Sorafenib—thyroid cancer	0.00343	0.00343	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Doxorubicin—thyroid cancer	0.00334	0.00334	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00333	0.00333	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Epirubicin—thyroid cancer	0.00332	0.00332	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00329	0.00329	CcSEcCtD
Desvenlafaxine—Diarrhoea—Sorafenib—thyroid cancer	0.00327	0.00327	CcSEcCtD
Desvenlafaxine—Breast disorder—Epirubicin—thyroid cancer	0.00325	0.00325	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00324	0.00324	CcSEcCtD
Desvenlafaxine—Dizziness—Sorafenib—thyroid cancer	0.00316	0.00316	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00307	0.00307	CcSEcCtD
Desvenlafaxine—Vomiting—Sorafenib—thyroid cancer	0.00304	0.00304	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00304	0.00304	CcSEcCtD
Desvenlafaxine—Rash—Sorafenib—thyroid cancer	0.00302	0.00302	CcSEcCtD
Desvenlafaxine—Dermatitis—Sorafenib—thyroid cancer	0.00301	0.00301	CcSEcCtD
Desvenlafaxine—Breast disorder—Doxorubicin—thyroid cancer	0.00301	0.00301	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.003	0.003	CcSEcCtD
Desvenlafaxine—Headache—Sorafenib—thyroid cancer	0.003	0.003	CcSEcCtD
Desvenlafaxine—Nausea—Sorafenib—thyroid cancer	0.00284	0.00284	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00284	0.00284	CcSEcCtD
Desvenlafaxine—Weight increased—Epirubicin—thyroid cancer	0.00283	0.00283	CcSEcCtD
Desvenlafaxine—Weight decreased—Epirubicin—thyroid cancer	0.00281	0.00281	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00275	0.00275	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00263	0.00263	CcSEcCtD
Desvenlafaxine—Weight increased—Doxorubicin—thyroid cancer	0.00262	0.00262	CcSEcCtD
Desvenlafaxine—Epistaxis—Epirubicin—thyroid cancer	0.00261	0.00261	CcSEcCtD
Desvenlafaxine—Weight decreased—Doxorubicin—thyroid cancer	0.0026	0.0026	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Epirubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Epirubicin—thyroid cancer	0.00245	0.00245	CcSEcCtD
Desvenlafaxine—Urethral disorder—Epirubicin—thyroid cancer	0.00244	0.00244	CcSEcCtD
Desvenlafaxine—Epistaxis—Doxorubicin—thyroid cancer	0.00242	0.00242	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Epirubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Desvenlafaxine—Eye disorder—Epirubicin—thyroid cancer	0.00233	0.00233	CcSEcCtD
Desvenlafaxine—Tinnitus—Epirubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Desvenlafaxine—Angiopathy—Epirubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Desvenlafaxine—Urethral disorder—Doxorubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Desvenlafaxine—Immune system disorder—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Chills—Epirubicin—thyroid cancer	0.00223	0.00223	CcSEcCtD
Desvenlafaxine—Alopecia—Epirubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Desvenlafaxine—Mental disorder—Epirubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Doxorubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Desvenlafaxine—Malnutrition—Epirubicin—thyroid cancer	0.00217	0.00217	CcSEcCtD
Desvenlafaxine—Eye disorder—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Desvenlafaxine—Tinnitus—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Desvenlafaxine—Tension—Epirubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Desvenlafaxine—Dysgeusia—Epirubicin—thyroid cancer	0.00212	0.00212	CcSEcCtD
Desvenlafaxine—Nervousness—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Desvenlafaxine—Angiopathy—Doxorubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Desvenlafaxine—Immune system disorder—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Desvenlafaxine—Chills—Doxorubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Desvenlafaxine—Vision blurred—Epirubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Desvenlafaxine—Alopecia—Doxorubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Desvenlafaxine—Mental disorder—Doxorubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Desvenlafaxine—Malnutrition—Doxorubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Desvenlafaxine—Tension—Doxorubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Desvenlafaxine—Dysgeusia—Doxorubicin—thyroid cancer	0.00196	0.00196	CcSEcCtD
Desvenlafaxine—Nervousness—Doxorubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Desvenlafaxine—Vertigo—Epirubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Desvenlafaxine—Syncope—Epirubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Desvenlafaxine—Palpitations—Epirubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Epirubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Desvenlafaxine—Vision blurred—Doxorubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Desvenlafaxine—Convulsion—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Desvenlafaxine—Hypertension—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Desvenlafaxine—Anxiety—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Desvenlafaxine—Dry mouth—Epirubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Vertigo—Doxorubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Syncope—Doxorubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Desvenlafaxine—Palpitations—Doxorubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Doxorubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Desvenlafaxine—Shock—Epirubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Desvenlafaxine—Convulsion—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Epirubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Desvenlafaxine—Hypertension—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Desvenlafaxine—Tachycardia—Epirubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Desvenlafaxine—Skin disorder—Epirubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Epirubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Desvenlafaxine—Anxiety—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Desvenlafaxine—Dry mouth—Doxorubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Desvenlafaxine—Shock—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Doxorubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Insomnia—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Tachycardia—Doxorubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Skin disorder—Doxorubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Desvenlafaxine—Paraesthesia—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Desvenlafaxine—Somnolence—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Desvenlafaxine—Decreased appetite—Epirubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Desvenlafaxine—Fatigue—Epirubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Desvenlafaxine—Constipation—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Insomnia—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Desvenlafaxine—Paraesthesia—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Desvenlafaxine—Somnolence—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Desvenlafaxine—Decreased appetite—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Desvenlafaxine—Fatigue—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Desvenlafaxine—Constipation—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Desvenlafaxine—Asthenia—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Desvenlafaxine—Diarrhoea—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Desvenlafaxine—Asthenia—Doxorubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Desvenlafaxine—Dizziness—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Desvenlafaxine—Vomiting—Epirubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Desvenlafaxine—Diarrhoea—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Desvenlafaxine—Rash—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Desvenlafaxine—Dermatitis—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Desvenlafaxine—Headache—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Desvenlafaxine—Dizziness—Doxorubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Desvenlafaxine—Nausea—Epirubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Desvenlafaxine—Vomiting—Doxorubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Desvenlafaxine—Rash—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Desvenlafaxine—Dermatitis—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Desvenlafaxine—Headache—Doxorubicin—thyroid cancer	0.00102	0.00102	CcSEcCtD
Desvenlafaxine—Nausea—Doxorubicin—thyroid cancer	0.000972	0.000972	CcSEcCtD
